Key Points
- Casdin Partners Master Fund, L (reported as a director) bought 225,000 shares of Standard BioTools on Nov. 17 at $1.22, raising its stake to 62,975,000 shares valued at about $76.83 million (a 0.36% increase).
- The firm has been actively accumulating stock — roughly 2.78 million shares bought across multiple transactions from Aug. 25 to Nov. 17, spending about $3.36 million in total.
- Shares opened at $1.21 (down ~2.4%), and analysts have an average rating of "Reduce" with an average price target of about $1.35.
Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Casdin Partners Master Fund, L acquired 225,000 shares of the firm's stock in a transaction dated Monday, November 17th. The stock was bought at an average price of $1.22 per share, for a total transaction of $274,500.00. Following the completion of the acquisition, the director owned 62,975,000 shares in the company, valued at approximately $76,829,500. The trade was a 0.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Casdin Partners Master Fund, L also recently made the following trade(s):
- On Friday, November 14th, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.24 per share, with a total value of $310,000.00.
- On Thursday, November 13th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.20 per share, for a total transaction of $540,000.00.
- On Wednesday, November 12th, Casdin Partners Master Fund, L purchased 375,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.19 per share, for a total transaction of $446,250.00.
- On Tuesday, November 11th, Casdin Partners Master Fund, L purchased 300,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.20 per share, with a total value of $360,000.00.
- On Monday, November 10th, Casdin Partners Master Fund, L acquired 275,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.17 per share, for a total transaction of $321,750.00.
- On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.12 per share, for a total transaction of $252,000.00.
- On Tuesday, September 9th, Casdin Partners Master Fund, L bought 100,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.29 per share, with a total value of $129,000.00.
- On Wednesday, September 3rd, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.27 per share, for a total transaction of $317,500.00.
- On Tuesday, August 26th, Casdin Partners Master Fund, L purchased 125,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.26 per share, for a total transaction of $157,500.00.
- On Monday, August 25th, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.24 per share, with a total value of $248,000.00.
Standard BioTools Stock Down 2.4%
Shares of LAB opened at $1.21 on Tuesday. Standard BioTools Inc. has a fifty-two week low of $0.92 and a fifty-two week high of $2.25. The firm's 50 day moving average price is $1.28 and its 200 day moving average price is $1.23. The company has a market cap of $465.32 million, a P/E ratio of -3.78 and a beta of 1.25.
Institutional Trading of Standard BioTools
Institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC boosted its position in shares of Standard BioTools by 6.1% during the 2nd quarter. Intech Investment Management LLC now owns 149,018 shares of the company's stock worth $179,000 after acquiring an additional 8,519 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in Standard BioTools by 50.3% during the second quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company's stock worth $36,000 after purchasing an additional 9,986 shares during the last quarter. HighTower Advisors LLC boosted its holdings in Standard BioTools by 10.8% in the first quarter. HighTower Advisors LLC now owns 102,791 shares of the company's stock valued at $111,000 after purchasing an additional 10,000 shares in the last quarter. Federated Hermes Inc. increased its stake in Standard BioTools by 103.6% in the third quarter. Federated Hermes Inc. now owns 28,545 shares of the company's stock valued at $37,000 after purchasing an additional 14,523 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd increased its stake in Standard BioTools by 115.6% in the first quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock valued at $29,000 after purchasing an additional 14,541 shares during the last quarter. 53.74% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
LAB has been the topic of a number of recent research reports. Wall Street Zen lowered Standard BioTools from a "hold" rating to a "strong sell" rating in a research report on Saturday, November 8th. Cowen lowered Standard BioTools from a "buy" rating to a "hold" rating in a research report on Wednesday, August 13th. TD Cowen decreased their price objective on Standard BioTools from $1.55 to $1.35 and set a "hold" rating for the company in a research note on Wednesday, November 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Reduce" and an average price target of $1.35.
Read Our Latest Research Report on Standard BioTools
About Standard BioTools
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
